Maraviroc (Celsentri)

Maraviroc (known by the trade name Celsentri in Europe and Selzentry in the United States) is the first drug to be licensed from a new class of antiretrovirals called CCR5 inhibitors. Maraviroc prevents HIV from entering uninfected cells by blocking the predominant route of entry on the surface of some immune cells, the CCR5 receptor.

In 2007, the drug was approved for use in combination with other antiretrovirals, by treatment-experienced individuals with a confirmed CCR5-tropic virus in the US and marketing approval in Europe for treatment-experienced people followed soon after. Maraviroc received licensing for use in antiretroviral-naive patients in the US in November 2009.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.